Kineret For Rheumatoid Arthritis
A New Kid On The Block

Medical Author: William C. Shiel Jr., MD, FACP, FACR
Medical Editor: Leslie J. Schoenfield, MD, PhD

A new drug is available for adult patients with moderate to severe rheumatoid arthritis who have not responded to other disease modifying antirheumatic drugs (DMARDs)! The brand name of the new drug is Kineret and its generic name is anakinra.

This is big news in the treatment of rheumatoid arthritis. You see, anakinra (Kineret) is a new type of biological response modifier (BRM) for treating this disease. Thus, anakinra (Kineret) acts by blocking the biological effects of the chemical messenger, Interleukin-1 (IL-1). IL-1 is a protein that is produced by many cells in the body. It is found, however, in increased amounts within joints that are inflamed by rheumatoid arthritis. In fact, IL-1 promotes the inflammation and destruction of cartilage and bone in rheumatoid arthritis. Accordingly, this BRM, like the traditional DMARDS, can prevent progressive joint destruction.